“Obtaining FDA authorization for AspyreRx was a pivotal milestone for our company and a catalyst for strengthening our financial position and advancing business development discussions,” said Frank Karbe, Chief Executive Officer at Better Therapeutics. “With a commercial release of AspyreRx anticipated later this year, gaining broad payer coverage and building awareness amongst targeted healthcare providers is a key priority for us.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BTTX: